Wyniki wyszukiwania - Biblioteka Nauki

1

The physical and occupational activity of patients with multiple sclerosis depending on the form of clinical disease

100%

Wyszyńska E. , Sienkiewicz D. , Kułak W.

Progress in Health Sciences

|

2019

|

tom 1

126-131

EN

Introduction: The progressive nature of multiple sclerosis (MS) is associated with numerous neurological deficits, leading gradually to deteriorating health and to disability. Purpose: The aim of this study was a subjective assessment of the physical and occupational activity of individuals with MS depending on the clinical form of the disease. Materials and methods: We used the original to conduct the research, with 28 closed questions. The study was carried out from December 1, 2018, to January 31, 2019, following approval by the Bioethics Committee of the Medical University of Bialystok, among persons belonging to the Association for Helping Sick People for Multiple Sclerosis in Białystok and patients of the Neurology Department of the University Clinical Hospital in Bialystok. The study sample comprised 50 people diagnosed with MS, 41 women and 9 men. Results: The most frequently occurring clinical form of MS was relapsing-remitting (68%). In this form, most participants had good physical fitness (44%). In those with the progressive-recurrent form (50%), very poor physical fitness was subjectively noted. Of those with the relapsing-remitting type of MS, 50% were professionally active, while none of the participants with the progressive-recurrent form were. Both the physical and occupational activities of MS patients were frequently limited by fatigue, balance disturbances, and movement difficulties. Fatigue was the most common symptom for most individuals with MS (82%). Conclusion: MS has a significant impact on both the physical activity and occupational functioning of patients. In the clinical form of MS, relapsing-remitting, patients’ physical fitness was better.

2

ESTIMATION OF POSTURAL STABILITY OF A PATIENT WITH MULTIPLE SCLEROSIS DURING A REHABILITATION PROGRAM - CASE STUDY

100%

BUTELSKA A. , ZYZNAWSKA J. , BOBER A. , BĄK S. , MAŃKO G.

Medicina Internacia Revuo

|

2013

|

tom 25

|

nr 101

220- 229

EN

Background and purpose: Multiple sclerosis (MS) is a demyelinating disease, usually with multifocal symptoms and multiphasic course that is emerging as a result of inflammation and the formation of foci of myelin breakdown in the central nervous system as a consequence of not fully known harmful external factors. The aim of this study was to analyze the results of tests allowing to detect imbalances in patients with multiple sclerosis. Material and Methods: A 38 year old male with MS diagnosed in 2006 was examined. The study used three tests of balance: "Timed Up & Go" test, Tinetti test and Berg Balance Scale. The results of the scale were analyzed, which consisted in a variety of motor tasks assessing balance and gait. Tests were repeated every month for 10 months. Results: The results in each test over 10 months significantly change. Changes in response to the increase of the number of tasks and the difficulty of the test occured. As a consequence of impaired balance control, the number of falls increased. Conclusions: The stability of the patient with multiple sclerosis is getting worse in each test evaluated. The deficit of stability increased in response to increasing the number of tasks and increasing the difficulty of the test. A key role in postural stability in standing plays the pelvis and lumbo-pelvic-hip complex.

3

CSF and serum total-tau and phospho-tau(181P) in MS patients

100%

Jaworski J. , Psujek M. , Bartosik-Psujek H.

Open Medicine

|

2011

|

tom 6

|

nr 2

193-200

EN

In search of biological marker in multiple sclerosis (MS), total-tau and phospho-tau (Thr181) concentrations were established in CSF and serum of 78 patients with MS, using commercially available kits. Serum and CSF concentrations of IgG, IgM, and albumin were assayed simultaneously to calculate quotients and indices of intrathecal synthesis. Serum t-tau detection was strikingly low (23.1%); therefore, this factor was excluded from further analysis. Serum p-tau levels did not correlate with any of indices or quotients. Unexpectedly, CSF t-tau and p-tau showed an inverse relation with MSSS and EDSS, which has not been published elsewhere. Our results do not support utility of serum t-tau and p-tau as surrogate markers for MS.

4

Annexin V antibodies in multiple sclerosis and SLE/APS

100%

Baleva M. , Stoilova D. , Shotekov P. , Nikolov K.

Open Medicine

|

2013

|

tom 8

|

nr 2

225-228

EN

Multiple sclerosis (MS) is an autoimmune disease with unclear etiopathogenesis. Some MS patients have anticardiolipin (ACL), anti-beta-2-glycoprotein-I (B2GPI) and anti-annexin V (AnV) antibodies. These antibodies can also be found in systemic lupus erythematosus with antiphospholipid syndrome (SLE/APS). The aim of our study was to compare the levels of ACL, B2GPI and AnV antibodies in MS and SLE/APS. Materials and methods: We investigated serum levels of IgG and IgM ACL, B2GPI and AnV in 21 MS patients, 30 SLE/APS patients and 30 controls using ELISA. Results: Mean levels of IgM and IgG ACL and B2GPI in MS were comparable with controls and lower than SLE/APS (p<0.05). Mean levels of IgM AnV in MS were higher compared to SLE/APS and controls (p<0.05); mean levels of IgG AnV in MS were higher than normal but similar to SLE/APS (p>0.05). Discussion: The results show that MS with negative “classic” autoantibodies (ACL and B2GPI) and without clinical data for antiphospholipid syndrome may have other positive antiphospholipid antibodies, such as AnV. Larger studies are needed to clarify whether AnV are epiphenomenon of the vascular and organ damage or they play a pathogenic role in the development of MS.

5

Anxiety and social activities in multiple sclerosis patients

100%

Leonavičius R. , Adomaitienė V.

Open Medicine

|

2013

|

tom 8

|

nr 1

56-61

EN

Despite that the prevalence of depression has been thoroughly analyzed in multiple sclerosis (MS) patients and affects approximately 15%–20% of the MS population, attention paid to social activities concomitant with anxiety is still too sporadic. The aim of this study was to find the prevalence of anxiety and social activities aggraded/aggravated with anxiety in the MS population in Lithuania and to analyze how it correlates with socio-demographic factors, clinical outcomes of MS and depression. Three hundred twelve MS patients took part in this study; anxiety prevalence was pointed in 20.2%. Only 23.4% of the study population was socially active. Our study shows a significant level of anxiety and low level of social activity in people with MS. Anxiety in MS patients was strongly related with younger age, shorter MS duration, prevalence of depression and lower level of social activity. A higher level of social activity was significantly related with older urban MS patients who indicated family status as living together and longer MS duration.

6

Impact of depression on multiple sclerosis patients

100%

Leonavičius R. , Adomaitienė V.

Open Medicine

|

2012

|

tom 7

|

nr 5

685-690

7

The relationships between depression and life activities and well-being of multiple sclerosis patients

88%

Leonavičius R. , Adomaitienė V. , Leskauskas D.

Open Medicine

|

2011

|

tom 6

|

nr 5

652-661

EN

Multiple sclerosis (MS) is one of the most disabling neurodegenerative disorders. Depression is the most frequent psychiatric disorder accompanying MS. Although much attention is given to correlations between depression and MS clinical factors, analysis of correlations between depression and life activities (social, household, professional activities and family life) and the well-being of MS patients’ is insufficient. However, improvement of these functions could positively influence the outcomes of MS treatment. The aim of this study was to evaluate relationships between depression, life activities of MS patients, and their proposals how to improve the well-being. Materials and methods. The study lasted three years with 270 adult MS patients involved in it. ICD-10 criteria were used to diagnose depression. Original questionnaire was used to measure life activities and the well-being of the patients. Results. Prevalence of depression was 20.7% with no difference regarding the gender. Almost 84% of depressed respondents indicated, that MS disturbs their family life, 71.4% recommended to assign more attention to MS in general and 64.3% - to include more medications into reimbursement list. Conclusions. MS patients diagnosed with depression significantly more often than non-depressed indicate that MS disturbs their family life; recommend to assign more attention to MS in general and to include more medications into reimbursement list.

8

Acute abdomen due to bladder perforation in a patient with multiple sclerosis

88%

Habek D. , Pavelić-Turudić T. , Vukelić M. , Mazul-Sunko B.

Open Medicine

|

2013

|

tom 8

|

nr 3

362-363

EN

The authors presented a case report of the acute abdomen with pelvic abscess because bladder perforation in a 21-year-old patient with multiple sclerosis and intermittent catheterization of the urinary bladder.

9

Progressive forms of multiple sclerosis: disease-modifying therapy review

88%

Sapko K. , Szczepańska-Szerej A. , Jamroz-Wiśniewska A. , Kulczyński M. , Marciniec M. , Rejdak K.

World Scientific News

|

2018

|

tom 105

157-167

EN

Multiple sclerosis (MS) is a demyelinating, inflammatory, autoimmune disease of the central nervous system which affects most commonly young adults. It has wide spectrum of clinical and radiological presentations with relapses or steady progression. Recent years have brought new reports on the pathogenesis of MS. This systematized the current MS classification and created new parameters describing the course of the disease, such as activity and progression. Attention has been paid to the need for new drugs that focus on the treatment of progressive MS. Until now, the primary and secondary progressive MS have been somewhat forgotten, and most of modifying-disease drugs have been registered in the treatment of relapsing-remitting subtype. In recent years, not only new drug has been registered for the treatment of progressive MS (ocrelizumab) and another one is planned to be approved soon (siponimod), but also indications of old medicines (interferon-beta1b, cladribine, mitoxantrone, cyclophosphamide, azathioprine) have been extended. Despite intensive development, there is still a great need to seek new drugs that will stop the progression of disability in MS patients.

10

Sympathetic nervous system and neurotransmitters: their possible role in neuroimmunomodulation of multiple sclerosis and some other autoimmune diseases

75%

Markelov V. , Trushin M.

Open Medicine

|

2006

|

tom 1

|

nr 4

313-329

EN

Multiple sclerosis is still a disease without a cure. Although intensive research efforts have led to the development of drugs that modify the activity of the disease, most of them have various side effects and are expensive. At the same time it is becoming apparent that some remedies usually used to treat somatic and psychic disorders also have immunomodulating properties, and may help manage multiple sclerosis and other autoimmune diseases. We describe here the role of the sympathetic nervous system in the neuro-immune interaction in multiple sclerosis and other immune diseases with increased cellular immunity as well as neurochemical disturbances that take place in these disorders.

11

The comparisons of blood plasma and cerebrospinal fluid S100B protein concentrations in patients with Alzheimer`s disease, amyotrophic lateral sclerosis, and multiple sclerosis

75%

Tarasiuk J. , Kapica-Topczewska K. , Chorąży M. , Borowik-Zaręba A. , Mroczko B. , Kochanowicz J. , Kułakowska A.

Progress in Health Sciences

|

2019

|

tom 1

22-27

EN

Introduction:S100 calcium-binding protein B (S100B) is a biochemical marker of astroglial damage. Purpose: To assess the pathophysiological implications of S100B concentrations in blood plasma and cerebrospinal fluid of patients with neurodegenerative central nervous system disorders. Materials and Methods: In this study, we determined and compare S100B concentrations in blood plasma and cerebrospinal fluid obtained from subjects diagnosed with Alzheimer's disease (n=20), amyotrophic lateral sclerosis (n=12), multiple sclerosis (n=40) and the reference group (n=20), using enzyme-linked immunosorbent assay. Results: Concentrations of S100B in plasma collected from patients diagnosed with Alzheimer's disease (252,38±183,50 pg/mL) and multiple sclerosis (164,92±250,14 pg/mL) were above laboratory standards, but in patients with amyotrophic lateral sclerosis (53,96±56,92 pg/mL) and the reference group (2,12 pg/mL) were below laboratory norms (N>75 pg/mL). Concentrations of S100B in plasma collected from patients with Alzheimer's disease (252,38±183,50 pg/mL) were significantly higher than in patients with amyotrophic lateral sclerosis (53,96±56,92 pg/mL) (p<0,029). Concentrations of S100B in CSF collected from the reference group (546,96±236,62 pg/mL) and from patients with Alzheimer's disease (587,53±189,57 pg/mL), amyotrophic lateral sclerosis (404,41±179,56 pg/mL), multiple sclerosis (462,03±146,01 pg/mL) were very similar, and none of pairwise comparisons reached statistical significance. Conclusions: Results of our studies indicate the importance of S100B protein concentration assessment in blood in central nervous system disorders differential diagnostics.

12

Current Highlights in the Use of Magnetic Resonance Spectroscopy in Multiple Sclerosis

75%

Kulczyński M. , Walicka A. , Marciniec M. , Sapko K. , Dyndor K.

World Scientific News

|

2019

|

tom 134

|

nr 2

187-197

EN

Magnetic resonance spectroscopy is a non-invasive method used to measure concentrations of selected metabolites in brain such as: N-acetylaspartate, creatine, choline, glutamic acid, myo-inositol, lactic acid or γ-aminobutyric acid. The MRS allows the researcher to obtain information about biochemical composition in selected localizations of the examined CNS and is based on the interpretation of spectra of specific chemical compounds. The aim of this study is a literature review of papers from last 5 years involving the use of MRS in multiple sclerosis. Magnetic resonance spectroscopy is a modern, promising metabolomic imaging method enabling the assessment of brain metabolite concentrations and the dynamism of their changes in healthy people and patients suffering from multiple sclerosis at every stage of the disease. MRS is helpful not only in correlating changes in metabolite concentrations at various central nervous system locations with clinical manifestations, but is also an increasingly improving tool for predicting disease progression. Magnetic resonance spectroscopy may also be useful in more specific clinical situations such as differential diagnosis between multiple sclerosis and Devic’s syndrome or between tumefactive demyelinating lesions and gliomas. Especially in the latter case, the development of this technology may in the future result in the possibility of avoiding invasive biopsy in patients during the diagnosis of focal changes in the CNS. One should also not forget about the role that MRS may play in the future in monitoring the course of treatment with modern MS drugs, not only in everyday clinical practice but also at the stage of clinical trials. The development of fast MRS techniques, significantly shortening the acquisition time and 7 T magnetic resonance spectroscopy, precise and repeatable method of quantitative analysis of brain metabolites may be particularly helpful in achieving these goals.

13

REPRINT OF POLISH TRANSLATION OF ARTICLE BY ACCORD INTERNATIONAL ASSOCIATION FOR THE STUDY OF PAIN (IASP) - PAIN 154 (2013) 2691-2699 Migraine headaches and pain with neuropathic characteristics: Comorbid conditions in patients with multiple sclerosis

63%

Moisset X. , Ouchchane L. , Guy N. , Bayle D. J. , Dallel R. , Clavelou P.

Ból

|

2014

|

tom 15

|

nr 2

16-27

EN

We conducted a postal survey to assess the prevalence and characteristics of neuropathic pain and migraine in a cohort of multiple sclerosis (MS) patients. Of the 1300 questionnaires sent, 673 could be used for statistical analysis. Among the respondents, the overall pain prevalence in the previous month was 79%, with 51% experiencing pain with neuropathic characteristics (NCs) and 46% migraine. MS patients with both migraine and NC pain (32% of the respondents) reported more severe pain and had lower health-related quality of life than MS patients with either migraine or NC pain. Pain intensity in MS patients with migraine was moderate (6.0±0.1). Migraine was mostly episodic, but headaches were occurring on P15 days per month in 15% of those with migraine. MS patients with migraine were younger and had shorter disease durations than those with NC pain. NC pain was most often located in the extremities, back and head, and was frequently described as tingling and pins-and-needles. The intensity of NC pain was low to moderate (4.9±0.1), but positively correlated with the number of painful body sites. Nonetheless, patients with NC pain were more disabled (with a higher Expanded Disability Status Scale and pain interference index) than patients with migraine. Migraine, but not NC pain, was associated with age, disease duration, relapsing-remitting course, and interferon-beta treatment. This suggests that NC pain and migraine are mediated by different mechanisms. Therefore, pain mechanisms that specifically operate in MS patients need to be characterized to design optimal treatments for these individuals.

PL

Przeprowadziliśmy listowne badanie kwestionariuszowe w celu oceny częstości występowania i charakterystyki bólu neuropatycznego i migreny w kohorcie chorych na stwardnienie rozsiane (SR). Spośród wysłanych 1300 kwestionariuszy 673 nadawało się do analizy statystycznej. Ogólna częstość występowania bólu u respondentów w ciągu miesiąca poprzedzającego badanie wyniosła 79%; 51% badanych odczuwało ból o cechach neuropatycznych (BN), a 46% - ból migrenowy. Chorzy odczuwający zarówno ból migrenowy jak i BN (32% respondentów) zgłaszali większe natężenie bólu i gorszą jakość życia związaną ze stanem zdrowia niż pacjenci ze SR odczuwający tylko jeden z tych bólów. Natężenie bólu u chorych na SR i migrenę było umiarkowane (6,0±0,1). Migrena w większości przypadków miała charakter epizodyczny, ale u 15% osób z migreną bóle głowy występowały ≥15 dni w miesiącu. Chorzy na SR i na migrenę byli młodsi i chorowali krócej niż pacjenci z BN. Ból o charakterze neuropatycznym najczęściej umiejscowiony był w kończynach, plecach i głowie; często opisywany był jako mrowienie lub kłucie. Nasilenie BN było małe lub umiarkowane (4,9±0,1) ale korelowało z liczbą objętych bólem części ciała. Niemniej jednak pacjenci z BN byli bardziej niesprawni (mieli większą punktację w Expanded Disability Status Scale i w Pain Interference Index) niż pacjenci z migreną. W przeciwieństwie do BN, migrena była powiązana z wiekiem, czasem trwania choroby, postacią nawracająco-zwalniającą choroby oraz z leczeniem interferonem beta. Wskazuje to na odrębne mechanizmy BN i migreny. W związku z tym wydaje się konieczne scharakteryzowanie mechanizmów bólu, które działają swoiście u chorych na SR w celu opracowania optymalnego leczenia tych pacjentów.